Citations

Clear

2303 citation(s) found for "Yu, Edward".

2023 HRS/APHRS/LAHRS guideline on cardiac physiologic pacing for the avoidance and mitigation of heart failure
Chung, Mina K. , Lau, Chu‐Pak, Forno, Alexander Romeno Janner Dal, Arora, Vanita , Birgersdotter‐Green, Ulrika , Cha, Yong‐Mei , Chung, Eugene H. , Cronin, Edmond M. , Curtis, Anne B. , Cygankiewicz, Iwona , Dandamudi, Gopi, Dubin, Anne M. , Ensch, Douglas P., Glotzer, Taya V. , Gold, Michael R. , Goldberger, Zachary D. , Gutiérrez, Alejandra , Guzmán, Juan C. , Indik, Julia H. , Karpawich, Peter P. , Khaykin, Yaariv , Kiehl, Erich L., Kutyifa, Valentina , Müllens, Wilfried , Parkash, Ratika , Patete, Manuel , Pathak, Rajeev K. , Perona, Carlos, Rickard, John , Schoenfeld, Mark H., Seow, Swee‐Chong , Shen, Win‐Kuang , Slotwiner, David J. , Sridhar, Arun Raghav Mahankali , Srivatsa, Uma N. , Stecker, Eric C. , Tanawuttiwat, Tanyanan , Tapias, Carlos A., Upadhyay, Gaurav A. , Vernooy, Kevin , Worsnick, Sarah Ann, Zaręba, Wojciech , Zeitler, Emily P. , Reviewers, Document, López-Cabanillas, Néstor , Ellenbogen, Kenneth A. , Hua, Wei , Ikeda, Takanori , Mackall, Judith A. , Mela, Theofanie , Racenet, Laurel Kay, Mason, Pamela K, Moore, Jeremy P. , Dubin, Anne M , Zareba, Wojciech , Pathak, Rajeev K , Ellenbogen, Kenneth A , Patton, Kristen K. , Forno, Alexander Dal , Al‐Khatib, Sana M. , Ensch, Douglas P., Gopinathannair, Rakesh , Gorodeski, Eiran Z. , Huang, Weijian , Imrey, Peter B. , Karim, Saima , Kron, Jordana , Link, Mark S. , Marine, Joseph Edward , Park, Seung‐Jung , Shoda, Morio , Singh, Jagmeet P , Tang, W.H. Wilson , Tracy, Cynthia M. , Varma, Niraj , Vijayaraman, Pugazhendhi , Reviewers, Document, Mason, Pamela Kay , McLeod, Christopher J.

Mayo Clinic

Journal of Arrhythmia | May 20, 2023 | Volume: 39 | Issue: 5 | Pages: 681-756

10.1002/joa3.12872 | PMID 37799799 Get It

AbstractCardiac physiologic pacing (CPP), encompassing cardiac resynchronization therapy (CRT) and conduction system pacing (CSP), has emerged as a pacing therapy strategy that may mitigate or prevent the development of heart failure (HF) in patients with ventricular dyssynchrony or pacing‐induced cardiomyopathy. This clinical practice guideline is intended to provide guidance on indications for CRT for HF therapy and CPP in patients with pacemaker indications or HF, patient selection, pre‐procedure evaluation and preparation, implant procedure management, follow‐up evaluation and optimization of CPP response, and use in pediatric populations. Gaps in knowledge, pointing to new directions for future research, are also identified.
Safety and Activity of Immune Checkpoint Inhibitors in People Living With HIV and Cancer: A Real-World Report From the Cancer Therapy Using Checkpoint Inhibitors in People Living With HIV-International (CATCH-IT) Consortium
Zarif, Talal El , Nassar, Amin H. , Adib, Elio , Fitzgerald, Bailey G. , Huang, Jiaming , Mouhieddine, Tarek H. , Rubinstein, P , Nonato, Taylor K., McKay, Rana R. , Li, Mingjia , Baiocchi, Robert A. , Lorentsen, Michael , Dittus, Christopher , Dizman, Nazlı , Falohun, Adewunmi, Abdel‐Wahab, Noha , Diab, Adi , Bankapur, Anand, Reed, Alexandra, Kim, Chul , Arora, Aakriti, El‐Am, Edward , Abdallah, Wassim , Al‐Hader, Ahmad, Ghazal, Batool Abu, Drolen, Claire , Drakaki, Alexandra , Baena, Javier , Nebhan, Caroline A. , Haykal, Tarek , Morse, Michael A. , Cortellini, Alessio , Pinato, David J. , Pria, Alessia Dalla , Bakalov, Veli , Bahary, Nathan , Rajkumar, Aarthi , Mangla, Ankit , Singh, Parminder , Nana, Frank Aboubakar , Lopetegui‐Lia, Nerea , Dobbs, Ryan W. , Funchain, Pauline , Long, Georgina V. , Genova, Carlo , Barletta, Giulia, Idossa, Damé , Lamberti, Giuseppe , Freeman, Dory , Chiao, Elizabeth Y. , Johnson, Douglas B. , Ramaswami, Ramya , Bower, Mark , Emu, Brinda , Baden, Lindsey R. , Sonpavde, Guru , Naqash, Abdul Rafeh , El Zarif, Talal , Rubinstein, Paul G , Mittra, Arjun , Owen, Dwight H , Lorentsen, Michael , Dittus, Christopher , Dizman, Nazli , Abdel-Wahab, Noha , Diab, Adi , Kim, Chul , Shah, Neil J , Kozaily, Elie , Abdallah, Wassim , Saeed, Anwaar , Drolen, Claire , Lechner, Melissa G , Drakaki, Alexandra , Nebhan, Caroline A , Haykal, Tarek , Cortellini, Alessio , Pinato, David J , Dalla Pria, Alessia , Hall, Evan , Bahary, Nathan , Mangla, Ankit , Shah, Vishal , Aboubakar Nana, Frank , Lopetegui-Lia, Nerea , Dima, Danai , Dobbs, Ryan W , Funchain, Pauline , Woodford, Rachel , Long, Georgina V , Menzies, Alexander M , Genova, Carlo , Puri, Sonam , Florou, Vaia , Lamberti, Giuseppe , Addeo, Alfredo , Bersanelli, Melissa , Xie, Wanling , Reid, Erin G , Chiao, Elizabeth Y , Sharon, Elad , Johnson, Douglas B , Ramaswami, Ramya , Bower, Mark , Choueiri, Toni K , Lurain, Kathryn , Sonpavde, Guru , Naqash, Abdul Rafeh , Nassar, Amin H. , Singh, Parminder , Saeed, Anwaar , Shah, Vishal , Dima, Danai , Saleem, Rabia, Saponara, Maristella , Queirolo, Paola , Addeo, Alfredo , Xie, Wanling , Sharon, Elad , Marron, Thomas , Choueiri, Toni K. , Espinar, Javier Baena

Mayo Clinic

Journal of Clinical Oncology | May 16, 2023 | Volume: 41 | Issue: 21 | Pages: 3712-3723

10.1200/jco.22.02459 | PMID 37192435 Get It

PURPOSE Compared with people living without HIV (PWOH), people living with HIV (PWH) and cancer have traditionally been excluded from immune checkpoint inhibitor (ICI) trials. Furthermore, there is a paucity of real-world data on the use of ICIs in PWH and cancer. METHODS This retrospective study included PWH treated with anti–PD-1- or anti–PD-L1-based therapies for advanced cancers. Kaplan-Meier method was used to estimate overall survival (OS) and progression-free survival (PFS). Objective response rates (ORRs) were measured per RECIST 1.1 or other tumor-specific criteria, whenever feasible. Restricted mean survival time (RMST) was used to compare OS and PFS between matched PWH and PWOH with metastatic NSCLC (mNSCLC). RESULTS Among 390 PWH, median age was 58 years, 85% (n = 331) were males, 36% (n = 138) were Black; 70% (n = 274) received anti–PD-1/anti–PD-L1 monotherapy. Most common cancers were NSCLC (28%, n = 111), hepatocellular carcinoma ([HCC]; 11%, n = 44), and head and neck squamous cell carcinoma (HNSCC; 10%, n = 39). Seventy percent (152/216) had CD4+ T cell counts ≥200 cells/µL, and 94% (179/190) had HIV viral load <400 copies/mL. Twenty percent (79/390) had any grade immune-related adverse events (irAEs) and 7.7% (30/390) had grade ≥3 irAEs. ORRs were 69% (nonmelanoma skin cancer), 31% (NSCLC), 16% (HCC), and 11% (HNSCC). In the matched mNSCLC cohort (61 PWH v 110 PWOH), 20% (12/61) PWH and 22% (24/110) PWOH had irAEs. Adjusted 42-month RMST difference was –0.06 months (95% CI, –5.49 to 5.37; P = .98) for PFS and 2.23 months (95% CI, –4.02 to 8.48; P = .48) for OS. CONCLUSION Among PWH, ICIs demonstrated differential activity across cancer types with no excess toxicity. Safety and activity of ICIs were similar between matched cohorts of PWH and PWOH with mNSCLC.
P56 SURVIVAL BENEFIT OF BIRTAMIMAB IN MAYO STAGE IV AL AMYLOIDOSIS IN THE PHASE 3 VITAL STUDY WAS CONSISTENT ACROSS ALL KEY BASELINE VARIABLES
Comenzo, Raymond L. , Landau, Heather , Libby, Edward N., Liedtke, Michaela , Wechalekar, Ashutosh , Zonder, Jeffrey A. , Nie, C. , Karp, Carol L. , Jin, Yu , Conrad, Anne , Kinney, Gene G. , Gertz, Morie A. , Cohen, Adam D. , Kastritis, Efstathios , Sanchorawala, Vaishali , Schönland, Stefan , Wechalekar, Ashutosh D. , Ando, Yukio , Koh, Youngil , Palladini, Giovanni , Karp, C., Conrad, A., Merlini, Giampaolo

Mayo Clinic

HemaSphere | May 11, 2023 | Volume: 7 | Issue: S2 | Pages: 41-42

10.1097/01.hs9.0000936352.84768.4d Get It

Feasibility and acceptability of remote smartphone cognitive testing in frontotemporal dementia research
Taylor, Jack C. , Heuer, Hilary W. , Clark, Annie L , Wise, Amy B. , Manoochehri, Masood , Forsberg, Leah K. , Mester, Carly , Rao, Meghana , Brushaber, Daniell, Kramer, Joel H. , Welch, Ariane E., Kornak, John , Kremers, Walter K. , Domoto‐Reilly, Kimiko , Fields, Julie A. , Ghoshal, Nupur , Graff‐Radford, Neill R. , Hall, Matthew , Huey, Edward D. , Mackenzie, Ian R. , Masdeu, Joseph C. , Mendez, Mario F. , Onyike, Chiadi U. , Pascual, Belén , Pressman, Peter , Rankin, Katherine P. , Ratnasiri, Buddhika , Wong, Bonnie , Gorno‐Tempini, Maria Luisa , Rosen, Howard J. , Boxer, Adam L. , Staffaroni, Adam M. , Taylor, Jack Carson , Staffaroni, Adam M , Pascual, Belen , Kremers, Walter K , Domoto-Reilly, Kimiko , Brushaber, Danielle , Appleby, Brian S. , Dickerson, Bradford Clark , Grossman, Murray , Irwin, David J. , Lapid, Maria I. , Litvan, Irene , Masdeu, Joseph C , Nevler, Naomi , Rojas, Julio C. , Tartaglia, Maria Carmela , Boeve, Bradley F.

Mayo Clinic

Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring | May 10, 2023 | Volume: 15 | Issue: 2 | Pages: No page available

10.1002/dad2.12423 | PMID 37180971 Get It

AbstractIntroductionRemote smartphone assessments of cognition, speech/language, and motor functioning in frontotemporal dementia (FTD) could enable decentralized clinical trials and improve access to research. We studied the feasibility and acceptability of remote smartphone data collection in FTD research using the ALLFTD Mobile App (ALLFTD‐mApp).MethodsA diagnostically mixed sample of 214 participants with FTD or from familial FTD kindreds (asymptomatic: CDR®+NACC‐FTLD = 0 [N = 101]; prodromal: 0.5 [N = 49]; symptomatic ≥1 [N = 51]; not measured [N = 13]) were asked to complete ALLFTD‐mApp tests on their smartphone three times within 12 days. They completed smartphone familiarity and participation experience surveys.ResultsIt was feasible for participants to complete the ALLFTD‐mApp on their own smartphones. Participants reported high smartphone familiarity, completed ∼ 70% of tasks, and considered the time commitment acceptable (98% of respondents). Greater disease severity was associated with poorer performance across several tests.DiscussionThese findings suggest that the ALLFTD‐mApp study protocol is feasible and acceptable for remote FTD research.HIGHLIGHTS The ALLFTD Mobile App is a smartphone‐based platform for remote, self‐administered data collection. The ALLFTD Mobile App consists of a comprehensive battery of surveys and tests of executive functioning, memory, speech and language, and motor abilities. Remote digital data collection using the ALLFTD Mobile App was feasible in a multicenter research consortium that studies FTD. Data was collected in healthy controls and participants with a range of diagnoses, particularly FTD spectrum disorders. Remote digital data collection was well accepted by participants with a variety of diagnoses.
Tropifexor plus cenicriviroc combination versus monotherapy in nonalcoholic steatohepatitis: Results from the phase 2b TANDEM study
Anstee, Quentin M. , Lucas, Kathryn Jean , Francque, Sven , Sanyal, Arun J. , Ratziu, Vlad , Gadano, Adrián , Rinella, Mary E. , Charlton, Michael, Mena, Edward , Schattenberg, Jörn M. , Noureddin, Mazen , Lazas, Donald J., Sarin, Shiv K., Yılmaz, Yusuf , Stringer, Rowan , Kochuparampil, Jossy, Rodriguez‐Araujo, Gerardo, Chng, Elaine , Naoumov, Nikolai V. , Brass, Clifford A., Pedrosa, Marcos , Abdelmalek, Manal F. , Sanyal, A J , Ratziu, Vlad , Rinella, Mary , Loomba, Rohit , Schattenberg, Jörn M , Yilmaz, Yusuf , Stringer, Rowan , Chng, Elaine , Pedrosa, Marcos C , Anstee, Quentin M , Francque, Sven M , Loomba, Rohit , Goh, George Boon‐Bee , Sarin, Shiv Kumar , Martić, Miljen , Chen, Li

Mayo Clinic

Hepatology | May 10, 2023 | Volume: 78 | Issue: 4 | Pages: 1223-1239

10.1097/hep.0000000000000439 | PMID 37162151 Get It

Background and Aims: With distinct mechanisms of action, the combination of tropifexor (TXR) and cenicriviroc (CVC) may provide an effective treatment for NASH. This randomized, multicenter, double-blind, phase 2b study assessed the safety and efficacy of TXR and CVC combination, compared with respective monotherapies. Approach and Results: Patients (N = 193) were randomized 1:1:1:1 to once-daily TXR 140 μg (TXR140), CVC 150 mg (CVC), TXR 140 μg + CVC 150 mg (TXR140 + CVC), or TXR 90 μg + CVC 150 mg (TXR90 + CVC) for 48 weeks. The primary and secondary end points were safety and histological improvement, respectively. Rates of adverse events (AEs) were similar across treatment groups. Pruritus was the most frequently experienced AE, with highest incidence in the TXR140 group (40.0%). In TXR and combination groups, alanine aminotransferase (ALT) decreased from baseline to 48 weeks (geometric mean change: −21%, TXR140; −16%, TXR140 + CVC; −13%, TXR90 + CVC; and +17%, CVC). Reductions in body weight observed at week 24 (mean changes from baseline: TXR140, −2.5 kg; TXR140 + CVC, −1.7 kg; TXR90 + CVC, −1.0 kg; and CVC, −0.1 kg) were sustained to week 48. At least 1-point improvement in fibrosis stage/steatohepatitis resolution without worsening of fibrosis was observed in 32.3%/25.8%, 31.6%/15.8%, 29.7%/13.5%, and 32.5%/22.5% of patients in the TXR140, CVC, TXR140 + CVC, and TXR90 + CVC groups, respectively. Conclusions: The safety profile of TXR + CVC combination was similar to respective monotherapies, with no new signals. TXR monotherapy showed sustained ALT and body weight decreases. No substantial incremental efficacy was observed with TXR + CVC combination on ALT, body weight, or in histological end points compared with monotherapy.
Most Fractures Treated Nonoperatively in Individuals With Fibrodysplasia Ossificans Progressiva Heal With a Paucity of Flareups, Heterotopic Ossification, and Loss of Mobility
Lindborg, Carter M., Mukaddam, Mona Al , Baujat, Geneviève , Cunto, Carmen L. De, Delai, Patricia , Haga, Nobuhiko , Morhart, Rolf, Ruiter, Ruben D. de , Scott, Christiaan , Pignolo, Robert J. , Al Mukaddam, Mona, Cho, Tae‐Joon , Cunto, Carmen De , Eekhoff, Elisabeth M. W. , Hsiao, Edward C. , Seemann, Petra , Szczepanek, Małgorzata, Tabarkiewicz, Jacek , Kaplan, Frederick S.

Mayo Clinic

Clinical Orthopaedics & Related Research | May 8, 2023 | Volume: 481 | Issue: 12 | Pages: 2447-2458

10.1097/corr.0000000000002672 | PMID 37156007 Get It

Abstract Background Fibrodysplasia ossificans progressiva (FOP) is an ultrarare genetic disorder with episodic and progressive heterotopic ossification. Tissue trauma is a major risk factor for flareups, heterotopic ossification (HO), and loss of mobility in patients with FOP. The International Clinical Council on FOP generally recommends avoiding surgery in patients with FOP unless the situation is life-threatening, because soft tissue injury can trigger an FOP flareup. Surprisingly little is known about flareups, HO formation, and loss of mobility after fractures of the normotopic (occurring in the normal place, distinct from heterotopic) skeleton when treated nonoperatively in patients with FOP. Questions/purposes (1) What proportion of fractures had radiographic evidence of union (defined as radiographic evidence of healing at 6 weeks) or nonunion (defined as the radiographic absence of a bridging callus at 3 years after the fracture)? (2) What proportion of patients had clinical symptoms of an FOP flareup because of the fracture (defined by increased pain or swelling at the fracture site within several days after closed immobilization)? (3) What proportion of patients with fractures had radiographic evidence of HO? (4) What proportion of patients lost movement after a fracture? Methods We retrospectively identified 36 patients with FOP from five continents who sustained 48 fractures of the normotopic skeleton from January 2001 to February 2021, who were treated nonoperatively, and who were followed for a minimum of 18 months after the fracture and for as long as 20 years, depending on when they sustained their fracture during the study period. Five patients (seven fractures) were excluded from the analysis to minimize cotreatment bias because these patients were enrolled in palovarotene clinical trials (NCT02190747 and NCT03312634) at the time of their fractures. Thus, we analyzed 31 patients (13 male, 18 female, median age 22 years, range 5 to 57 years) who sustained 41 fractures of the normotopic skeleton that were treated nonoperatively. Patients were analyzed at a median follow-up of 6 years (range 18 months to 20 years), and none was lost to follow-up. Clinical records for each patient were reviewed by the referring physician–author and the following data for each fracture were recorded: biological sex, ACVR1 gene pathogenic variant, age at the time of fracture, fracture mechanism, fracture location, initial treatment modality, prednisone use at the time of the fracture as indicated in the FOP Treatment Guidelines for flare prevention (2 mg/kg once daily for 4 days), patient-reported flareups (episodic inflammatory lesions of muscle and deep soft connective tissue characterized variably by swelling, escalating pain, stiffness, and immobility) after the fracture, follow-up radiographs of the fracture if available, HO formation (yes or no) as a result of the fracture determined at a minimum of 6 weeks after the fracture, and patient-reported loss of motion at least 6 months after and as long as 20 years after the fracture. Postfracture radiographs were available in 76% (31 of 41) of fractures in 25 patients and were independently reviewed by the referring physician–author and senior author for radiographic criteria of fracture healing and HO. Results Radiographic healing was noted in 97% (30 of 31) of fractures at 6 weeks after the incident fracture. Painless nonunion was noted in one patient who sustained a displaced patellar fracture and HO. In seven percent (three of 41) of fractures, patients reported increased pain or swelling at or near the fracture site within several days after fracture immobilization that likely indicated a site-specific FOP flareup. The same three patients reported a residual loss of motion 1 year after the fracture compared with their prefracture status. HO developed in 10% (three of 31) of the fractures for which follow-up radiographs were available. Patient-reported loss of motion occurred in 10% (four of 41) of fractures. Two of the four patients reported noticeable loss of motion and the other two patients reported that the joint was completely immobile (ankylosis). Conclusion Most fractures treated nonoperatively in individuals with FOP healed with few flareups, little or no HO, and preservation of mobility, suggesting an uncoupling of fracture repair and HO, which are two inflammation-induced processes of endochondral ossification. These findings underscore the importance of considering nonoperative treatment for fractures in individuals with FOP. Physicians who treat fractures in patients with FOP should consult with a member of the International Clinical Council listed in the FOP Treatment Guidelines (https://www.iccfop.org). Level of Evidence Level IV, therapeutic study.
Postoperative Complication Impact on Quality of Life after Postmastectomy Breast Reconstruction
Zhang, Chi , Gomez, Diego A. , Abdulwadood, Isra , Reece, Edward, Rebecca, Alanna M. , Casey, William H. , Pockaj, Barbara A. , Gomez, Diego, Hammond, Jacob B. , Rebecca, Alanna, Casey, William, Gomez, Diego A , Kosiorek, Heidi , Cronin, Patricia

Mayo Clinic

Journal of the American College of Surgeons | May 5, 2023 | Volume: 237 | Issue: 2 | Pages: 319-330

10.1097/xcs.0000000000000739 | PMID 37146208 Get It

BACKGROUND: Although the overall psychosocial benefits and body image gains of postmastectomy breast reconstruction are well-established, there is limited information on how postoperative complications affect patient quality of life (QOL). STUDY DESIGN: A single-institution cross-sectional survey analysis was performed on patients who underwent postmastectomy breast reconstruction between 2008 and 2020. QOL was assessed using the BREAST-Q and the Was It Worth It questionnaires. The results were compared among patients who had major complications, minor complications, and no complications. Responses were compared using 1-way ANOVA and chi-square tests as appropriate. RESULTS: A total of 568 patients met inclusion criteria, and 244 patients responded (43% response rate). Most patients did not have any complications (n = 128; 52%), 41 had minor complications (17%), and 75 had major complications (31%). There were no differences in any of the BREAST-Q well-being metrics based on degree of complication. Across all 3 groups, patients reported that surgery was worthwhile (n = 212; 88%), they would choose reconstruction again (n = 203; 85%), and they would recommend it to a friend (n = 196; 82%). Overall, 77% reported that their overall experience either met or exceeded expectations, and 88% of patients had unchanged or improved overall QOL. CONCLUSIONS: Our study demonstrates that QOL and well-being are not negatively impacted by postoperative complications. Although patients who had no complications had an overall more positive experience, nearly two-thirds of all patients, no matter the degree of complication, stated that their overall experience either met or exceeded their expectations.
Recommendations for developing effective and safe paediatric and congenital heart disease services in low-income and middle-income countries: a public health framework
Hasan, Babar , Bhatti, Areesh, Mohsin, Shazia , Ahmed, Eltayeb Mohamed , Ali, Sulafa , Amanullah, Muneer , Ansong, Annette , Banu, Tahmina , Bolman, R. Morton , Borim, Bruna Cury , Callus, Edward , Caputo, Massimo , Hernández, Tomás Chalela, Croti, Ulisses Alexandre , Ejigu, Yayehyirad , Fenton, Kathleen N. , Gomanju, Anu , Harahsheh, Ashraf S. , Hesslein, Peter S., Hugo‐Hamman, Christopher , Kpodonu, Jacques , Malik, Mahim, Nichani, Sanjiv, Overman, David M. , Quenot, Alexis Palacios-Macedo, Bolman, Ceeya Patton, Pearson, Dorothy, Raju, Vijayakumar , Ross, Shelagh, Sandoval, Néstor , Shidhika, Fenny, Sivalingam, Sivakumar , Verstappen, Amy, Vervoort, Dominique , Zühlke, Liesl , Harahsheh, Ashraf S , Overman, David, Vervoort, Dominique , Zheleva, Bistra , Bhatti, Areesh, Barach, Paul Randall , Beaton, Andrea , Breinholt, John P. , Cardarelli, Marcelo G. , Khan, Sohail Hassan , Kumar, Raman , Jenkins, Kathy J. , Lakhoo, Kokila , Novick, William M. , Quenot, Alexis Palacios Macedo, Ross, Shelagh, Sholler, Gary F. , Sharma, Rajesh , Zheleva, Bistra

Mayo Clinic

BMJ Global Health | May 4, 2023 | Volume: 8 | Issue: 5 | Pages: e012049

10.1136/bmjgh-2023-012049 | PMID 37142298 Get It

The global burden of paediatric and congenital heart disease (PCHD) is substantial. We propose a novel public health framework with recommendations for developing effective and safe PCHD services in low-income and middle-income countries (LMICs). This framework was created by the Global Initiative for Children’s Surgery Cardiac Surgery working group in collaboration with a group of international rexperts in providing paediatric and congenital cardiac care to patients with CHD and rheumatic heart disease (RHD) in LMICs. Effective and safe PCHD care is inaccessible to many, and there is no consensus on the best approaches to provide meaningful access in resource-limited settings, where it is often needed the most. Considering the high inequity in access to care for CHD and RHD, we aimed to create an actionable framework for health practitioners, policy makers and patients that supports treatment and prevention. It was formulated based on rigorous evaluation of available guidelines and standards of care and builds on a consensus process about the competencies needed at each step of the care continuum. We recommend a tier-based framework for PCHD care integrated within existing health systems. Each level of care is expected to meet minimum benchmarks and ensure high-quality and family centred care. We propose that cardiac surgery capabilities should only be developed at the more advanced levels on hospitals that have an established foundation of cardiology and cardiac surgery services, including screening, diagnostics, inpatient and outpatient care, postoperative care and cardiac catheterisation. This approach requires a quality control system and close collaboration between the different levels of care to facilitate the journey and care of every child with heart disease. This effort was designed to guide readers and leaders in taking action, strengthening capacity, evaluating impact, advancing policy and engaging in partnerships to guide facilities providing PCHD care in LMICs.
Germline Genetic Testing in Unselected Squamous and Non‐Squamous Head and Neck Cancers
Brake, Daniela A. , Golafshar, Michael A. , Young, Sarah , Klint, Margaret, Barrus, Kathleen , Samadder, N. Jewel , Hinni, Michael L., Idler, Beau M. , Kunze, Katie L. , Chang, Brent A , Golafshar, Michael , Leach, Brandie , Esplin, Edward D. , Nussbaum, Robert L. , Chang, Brent A.

Mayo Clinic

The Laryngoscope | May 3, 2023 | Volume: 133 | Issue: 12 | Pages: 3378-3388

10.1002/lary.30720 | PMID 37132629 Get It

ObjectiveThis study describes the prevalence of pathogenic germline variants (PGVs) in head and neck cancer patients, the incremental yield compared to a guideline‐based approach to genetic evaluation, and the uptake of family variant testing.Study DesignProspective cohort study.SettingThree tertiary academic medical centers.MethodsGermline sequencing using an 84‐gene screening platform among unselected head and neck cancer patients who received care at Mayo Clinic Cancer Centers between April 2018 and March 2020.ResultsAmongst 200 patients, the median age was 62.0 years (Q1, Q3: 55, 71), 23.0% were female, 89.0% white/non‐Hispanic, 5.0% Hispanic/Latinx, 6% of another race, and 42.0% had prognostic stage IV disease. The most common subsites were the oropharyngeal (45.0%) and salivary glands (12.0%). The most common histology was squamous cell carcinoma (74.5%). Twenty‐one patients (10.5%) had a total of 22 PGVs; 20 of the 21 patients (95.2%) did not meet criteria for testing by current guidelines. Regarding penetrance of the 22 PGVs, 11 were high or moderate (most commonPMS2orHOXB13), and 11 were low or recessive (most commonMUTYH,WNR, orRECQL4). One patient had a change in care based on an identified PGV. Family variant testing was completed at a rate of 4.8%.ConclusionsUniversal gene panel testing identified a PGV in 10.5% of head and neck cancer patients; almost all would have been missed by current guideline‐based testing. One of 21 patients had a treatment change due to their PGV, indicating that head and neck cancer treatment decisions are not yet widely informed by germline alterations.Level of Evidence3Laryngoscope, 133:3378–3388, 2023
Same‐day discharge for left atrial appendage occlusion procedure: A systematic review and meta‐analysis
Khan, Jehanzeb Ahmed, Parmar, M. , Bhamare, Aditi, Agarwal, Siddharth , Khosla, Jagjit , Liu, Briana, Abraham, Rachel, Clifton, Shari , Munir, Muhammad Bilal , Deshmukh, Abhishek , Po, Sunny S. , Stavrakis, Stavros , DeSimone, Christopher V , Deshmukh, Abhishek J , Stavrakis, Stavros , Munir, Muhammad Bilal , Agarwal, Siddharth , Khan, Taha, DeSimone, Christopher V. , Asad, Zain Ul Abideen

Mayo Clinic

Journal of Cardiovascular Electrophysiology | May 2, 2023 | Volume: 34 | Issue: 5 | Pages: 1196-1205

10.1111/jce.15914 | PMID 37130436 Get It

AbstractIntroductionMost patients undergoing a left atrial appendage occlusion (LAAO) procedure are admitted for overnight observation. A same‐day discharge strategy offers the opportunity to improve resource utilization without compromising patient safety. We compared the patient safety outcomes and post‐discharge complications between same‐day discharge versus hospital admission (HA) (>1 day) in patients undergoing LAAO procedure.MethodsA systematic search of MEDLINE and Embase was conducted. Outcomes of interest included peri‐procedural complications, re‐admissions, discharge complications including major bleeding and vascular complications, ischemic stroke, all‐cause mortality, and peri‐device leak >5 mm. Mantel–Haenszel risk ratios (RRs) with 95% CIs were calculated.ResultsA total of seven observational studies met the inclusion criteria. There was no statistically significant difference between same‐day discharge versus HA regarding readmission (RR: 0.61; 95% confidence interval [CI]: [0.29–1.31]; p = .21), ischemic stroke after discharge (RR: 1.16; 95% CI: [0.49–2.73]), peri‐device leak >5 mm (RR: 1.27; 95% CI: [0.42–3.85], and all‐cause mortality (RR: 0.60; 95% CI: [0.36–1.02]). The same‐day discharge study group had significantly lower major bleeding or vascular complications (RR: 0.71; 95% CI: [0.54–0.94]).ConclusionsThis meta‐analysis of seven observational studies showed no significant difference in patient safety outcomes and post‐discharge complications between same‐day discharge versus HA. These findings provide a solid basis to perform a randomized control trial to eliminate any potential confounders.